ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO421

Clinical Efficacy of Fractionated Plasma Separation and Adsorption Integrated With Continuous Veno-Venous Hemofiltration in Patients With Liver Failure

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Dong, Jianhua, JinLing Hospital, Nanjing, Jiangsu, China
  • Huang, Li, JinLing Hospital, Nanjing, Jiangsu, China
  • Fan, Wenjing, JinLing Hospital, Nanjing, Jiangsu, China
  • Ge, Yongchun, JinLing Hospital, Nanjing, Jiangsu, China

To observe the clinical efficacy and safety of fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration (FPSA-CVVH) treatment on patients with liver failure.


In this retrospective study, we enrolled patients with acute or acute-on-chronic liver failure (serum total bilirubin>171.0μmol/L or MELD Score>18) hospitalized from 2015 to 2021. All patients received the treatment of FPSA-CVVH. The extracorporeal circulation connection is shown in Figure 1.Anticoagulation was provided with LMWH or citrate. The main efficacy evaluation index was bilirubin reduction ratios per session (RRs) .


78 patients with acute (n=74) or acute-on-chronic (n=4) liver failure were enrolled.Total bilirubin at baseline was 377.0±101.6 μmol/L, direct bilirubin was 279.3±78.7μmol/L and indirect bilirubin was 59.7±27.4μmol/L.187 sessions of FPSA-CVVH treatment were performed. After a single session total bilirubin (364.8±104.5μmol/L vs 170.8±57.3μmol/L), direct bilirubin (262.4±86.5μmol/L vs 102.5±46.4μmol/L) and indirect bilirubin (62.3±27.7μmol/L vs 35.9±14.8 μmol/L) significantly decreased. RRs was 52.0±7.6% for total bilirubin, 59.4±13.0% for direct bilirubin and 36.9±15.4% for indirect bilirubin. Mean arterial pressure and heart rate remained stable during the treatment. 2 patients changed the filters due to blood coagulation. And another 2 patients exhibited bleeding (gastrointestinal bleeding and Oozing bleeding).29 patients (37.2%) survived in discharging from hospital, 12 patients had recovered liver function,and the remaining 17 patients still needed intermittent artificial liver support therapy.


FPSA-CVVH treatment was a novol and effective artificial liver support therapy in patients with liver failure.Thus, it may be considered as a “bridge technique” to the recovery of liver and renal function in critical ill patients with liver failure.

Figure 1. Schematic diagram of combined continuous veno-venous hemofiltration- bilirubin adsorption